GlobeNewswire: Rain Oncology Inc. Contains the last 10 of 46 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T14:18:03ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2023/05/22/2673294/0/en/Rain-Oncology-Announces-Topline-Results-from-Phase-3-MANTRA-Trial-of-Milademetan-for-the-Treatment-of-Dedifferentiated-Liposarcoma.html?f=22&fvtc=4&fvtv=48083Rain Oncology Announces Topline Results from Phase 3 MANTRA Trial of Milademetan for the Treatment of Dedifferentiated Liposarcoma2023-05-22T12:00:00Z<![CDATA[– The Phase 3 MANTRA trial did not meet the primary endpoint of progression free survival vs. standard of care –]]>https://www.globenewswire.com/news-release/2023/05/11/2667285/0/en/Rain-Oncology-Reports-First-Quarter-2023-Financial-Results-and-Highlights-Recent-Progress.html?f=22&fvtc=4&fvtv=48083Rain Oncology Reports First Quarter 2023 Financial Results and Highlights Recent Progress2023-05-11T20:05:00Z<![CDATA[– Quarter-end cash position of $110 million provides runway to complete all ongoing and planned clinical trials of milademetan, including the Phase 3 MANTRA trial in liposarcoma, Phase 2 MANTRA-2 basket trial, and planned Phase 1/2 MANTRA-4 basket trial –]]>https://www.globenewswire.com/news-release/2023/04/24/2652642/0/en/Rain-Oncology-to-Report-First-Quarter-2023-Financial-Results-and-Highlights-Recent-Progress-on-May-11-2023.html?f=22&fvtc=4&fvtv=48083Rain Oncology to Report First Quarter 2023 Financial Results and Highlights Recent Progress on May 11, 20232023-04-24T12:00:00Z<![CDATA[NEWARK, Calif., April 24, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced it will report financial results for the first quarter ended March 31, 2023 and highlights of recent progress on Thursday, May 11, 2023. On that day, management will host a conference call and webcast at 2:00 pm PT (5:00 pm ET) to discuss the Company’s business and financial results.]]>https://www.globenewswire.com/news-release/2023/04/05/2641636/0/en/Rain-Oncology-Announces-Collaborator-Poster-Presentation-at-the-American-Association-for-Cancer-Research-AACR-Annual-Meeting-2023.html?f=22&fvtc=4&fvtv=48083Rain Oncology Announces Collaborator Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 20232023-04-05T12:00:00Z<![CDATA[NEWARK, Calif., April 05, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics with its lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced a poster presentation by Rain’s collaborators at Memorial Sloan Kettering Cancer Center (MSKCC) at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2023, being held at the Orange County Convention Center in Orlando, Florida from April 14-19, 2023.]]>https://www.globenewswire.com/news-release/2023/03/21/2631061/0/en/Rain-Oncology-Announces-Oral-Presentation-at-the-2023-ESMO-Sarcoma-and-Rare-Cancers-Annual-Congress.html?f=22&fvtc=4&fvtv=48083Rain Oncology Announces Oral Presentation at the 2023 ESMO Sarcoma and Rare Cancers Annual Congress2023-03-21T09:50:00Z<![CDATA[NEWARK, Calif., March 21, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics with its lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced an abstract accepted as a proffered paper presentation at the 2023 ESMO Sarcoma and Rare Cancers Annual Congress in Lugano, Switzerland.]]>https://www.globenewswire.com/news-release/2023/03/09/2624570/0/en/Rain-Oncology-Reports-Fourth-Quarter-and-Full-Year-2022-Financial-Results-and-Highlights-Recent-Progress.html?f=22&fvtc=4&fvtv=48083Rain Oncology Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Progress2023-03-09T21:05:00Z<![CDATA[– Year-end cash position of $130.5 million provides runway to complete all ongoing and planned clinical trials of milademetan, including the Phase 3 MANTRA trial in liposarcoma, Phase 2 MANTRA-2 basket trial, and planned Phase 1/2 MANTRA-4 basket trial –]]>https://www.globenewswire.com/news-release/2023/03/07/2621975/0/en/Rain-Oncology-to-Present-At-Oppenheimer-33rd-Annual-Healthcare-Conference.html?f=22&fvtc=4&fvtv=48083Rain Oncology to Present At Oppenheimer 33rd Annual Healthcare Conference2023-03-07T13:00:00Z<![CDATA[NEWARK, Calif., March 07, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics with its lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced that Avanish Vellanki, Chief Executive Officer of Rain, will be presenting a corporate overview at the Oppenheimer 33rd Annual Healthcare Conference on Monday, March 13, 2023, at 11:20 a.m. ET, in a virtual format.]]>https://www.globenewswire.com/news-release/2023/02/23/2614236/0/en/Rain-Oncology-to-Report-Fourth-Quarter-and-Full-Year-2022-Financial-Results-and-Highlights-of-Recent-Progress-on-March-9-2023.html?f=22&fvtc=4&fvtv=48083Rain Oncology to Report Fourth Quarter and Full Year 2022 Financial Results and Highlights of Recent Progress on March 9, 20232023-02-23T13:00:00Z<![CDATA[NEWARK, Calif., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced it will report financial results for the fourth quarter and full year ended December 31, 2022 and highlights of recent progress on Thursday, March 9, 2023. On that day, management will host a conference call and webcast at 2:00 pm PT (5:00 pm ET) to discuss the Company’s business and financial results.]]>https://www.globenewswire.com/news-release/2023/02/09/2604919/0/en/Rain-Oncology-to-Participate-in-the-2023-Citi-Virtual-Oncology-Leadership-Summit.html?f=22&fvtc=4&fvtv=48083Rain Oncology to Participate in the 2023 Citi Virtual Oncology Leadership Summit2023-02-09T13:00:00Z<![CDATA[NEWARK, Calif., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics with its lead product candidate, milademetan, an oral, small molecule inhibitor of the p53-MDM2 complex that reactivates p53, today announced that Avanish Vellanki, Chief Executive Officer of Rain, will be participating in a fireside chat at the Citi Virtual Oncology Leadership Summit on Tuesday, February 21, 2023, at 12:00 p.m. ET, being held virtually.]]>https://www.globenewswire.com/news-release/2023/01/31/2598987/0/en/UPDATE-Rain-Oncology-to-Participate-in-the-2023-Guggenheim-Healthcare-Talks-Oncology-Day-Conference.html?f=22&fvtc=4&fvtv=48083UPDATE – Rain Oncology to Participate in the 2023 Guggenheim Healthcare Talks Oncology Day Conference2023-01-31T21:27:32Z<![CDATA[NEWARK, Calif., Jan. 31, 2023 (GLOBE NEWSWIRE) -- In a release issued earlier today by Rain Oncology (NASDAQ: RAIN), the company is updating their presentation date and time to Thursday, February 9, 2023, at 3:55 p.m. ET.]]>